Recent studies show that dupilumab succeeded at treating moderate to severe eczema. The FDA approval of this drug is in the plans of Regeneron Pharmaceuticals (NASDAQ:REGN), and if it gets done, dupilumab could be next top seller for the company.
The studies of dupilumab –a agent that inhibits interleukin-4 and interleukin-13 – are focused on the treatment of a moderate to severe atopic dermatitis; which, according to the National Eczema Association, affects 17.8 million Americans.
Regeneron and its collaborator on this drug, Sanofi (NYSE:SNY), analyzed the use of dupilumab involving about 1,300 patients diagnosed with moderate to severe atopic dermatitis.
Atopic dermatitis is inherited and is chronic. It can appear all over the body, but it usually affects the inside of elbows, the face and the back of knees, and it normally develops in childhood and remains throughout a patient’s’ lifetime. Even when there’re treatments, such as topical creams, these only provide limited and inconsistent results.
The results of the studies indicate that the drug’s profile is strong and it could be a viable treatment option for 1.6 million of American patients.
Regeneron is climbing up
Regeneron is currently up by 11.8 percent after reporting positive late-stage trial results for the eczema treatment that’s being developed with SNY.
Holding Channels reports that during the fourth quarter, the position of Robeco Institutional Asset Management B.V increased by 38.5%. At the end of the most recent quarter, its holdings were worth $3,693,000.
Regeneron Pharmaceuticals, Inc –an integrated biopharmaceutical company – works discovering, inventing, developing, manufacturing and commercializing medicines for the treatment of serious medical conditions. Such as medicines for eye diseases, colorectal cancer, and a rare inflammatory condition.
Source: The Motley Fool